Similarly, Olsson et al. [13] also opined the nonassociation of UGT2B17 polymorphism with prostate cancer risk and, recently, Chew et al. [12] disregarded homozygous deletion genotype of UGT2B17 with osteoporosis risk. The gene discussed is UGT2B17; the disease is osteoporosis.